Metabolic Origins of Heart Failure

JACC: Basic to Translational Science

Volumn 2, Issue 3, 2017, Pages 297-310

  Wende, Adam R ^a   Brahma, Manoja K ^a   McGinnis, Graham R ^b   Young, Martin E ^b  

^a University of Alabama at Birmingham   (United States)

^b and Clinical Center   (United States)

Author keywords

amino acids; fatty acids; glucose; heart failure; ketone bodies

Indexed keywords

EID: 85033713530     PISSN: 2452302X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacbts.2016.11.009     Document Type: Review

References (143)

1. Brown, D.I., Griendling, K.K., Regulation of signal transduction by reactive oxygen species in the cardiovascular system. Circ Res 116 (2015), 531–549.
2. Bers, D.M., Cardiac sarcoplasmic reticulum calcium leak: basis and roles in cardiac dysfunction. Annu Rev Physiol 76 (2014), 107–127.
3. Lopaschuk, G.D., Ussher, J.R., Folmes, C.D., Jaswal, J.S., Stanley, W.C., Myocardial fatty acid metabolism in health and disease. Physiol Rev 90 (2010), 207–258.
4. Allard, M., Schonekess, B., Henning, S., English, D., Lopaschuk, G., Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol 267 (1994), H742–H750.
5. Goodwin, G., Taylor, C., Taegtmeyer, H., Regulation of energy metabolism of the heart during acute increase in heart work. J Biol Chem 273 (1998), 29530–29539.
6. Wisneski, J.A., Gertz, E.W., Neese, R.A., Mayr, M., Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans. J Clin Invest 79 (1987), 359–366.
7. Kato, T., Niizuma, S., Inuzuka, Y., et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail 3 (2010), 420–430.
8. Osorio, J.C., Stanley, W.C., Linke, A., et al. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 106 (2002), 606–612.
9. Davila-Roman, V.G., Vedala, G., Herrero, P., et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 40 (2002), 271–277.
10. Yazaki, Y., Isobe, M., Takahashi, W., et al. Assessment of myocardial fatty acid metabolic abnormalities in patients with idiopathic dilated cardiomyopathy using 123I BMIPP SPECT: correlation with clinicopathological findings and clinical course. Heart 81 (1999), 153–159.
11. Heather, L.C., Cole, M.A., Lygate, C.A., et al. Fatty acid transporter levels and palmitate oxidation rate correlate with ejection fraction in the infarcted rat heart. Cardiovasc Res 72 (2006), 430–437.
12. Sack, M.N., Rader, T.A., Park, S., Bastin, J., McCune, S.A., Kelly, D.P., Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94 (1996), 2837–2842.
13. Barger, P., Kelly, D., PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med 10 (2000), 238–245.
14. Lopaschuk, G., Belke, D., Gamble, J., Itoi, T., Schönekess, B., Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1213 (1994), 263–276.
15. Taegtmeyer, H., Overturf, M.L., Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension 11 (1988), 416–426.
16. Beer, M., Seyfarth, T., Sandstede, J., et al. Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol 40 (2002), 1267–1274.
17. Hirsch, G.A., Bottomley, P.A., Gerstenblith, G., Weiss, R.G., Allopurinol acutely increases adenosine triphosphate energy delivery in failing human hearts. J Am Coll Cardiol 59 (2012), 802–808.
18. Sharma, S., Adrogue, J., Golfman, L., et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 18 (2004), 1692–1700.
19. Abdurrachim, D., Luiken, J.J., Nicolay, K., Glatz, J.F., Prompers, J.J., Nabben, M., Good and bad consequences of altered fatty acid metabolism in heart failure: evidence from mouse models. Cardiovasc Res 106 (2015), 194–205.
20. Exil, V.J., Roberts, R.L., Sims, H., et al. Very-long-chain acyl-coenzyme a dehydrogenase deficiency in mice. Circ Res 93 (2003), 448–455.
21. Xiong, D., He, H., James, J., et al. Cardiac-specific VLCAD deficiency induces dilated cardiomyopathy and cold intolerance. Am J Physiol Heart Circ Physiol 306 (2014), H326–H338.
22. Noh, H.L., Okajima, K., Molkentin, J.D., Homma, S., Goldberg, I.J., Acute lipoprotein lipase deletion in adult mice leads to dyslipidemia and cardiac dysfunction. Am J Physiol Endocrinol Metab 291 (2006), E755–E760.
23. Ellis, J.M., Mentock, S.M., Depetrillo, M.A., et al. Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs Fatty Acid oxidation and induces cardiac hypertrophy. Mol Cell Biol 31 (2011), 1252–1262.
24. Kienesberger, P.C., Pulinilkunnil, T., Nagendran, J., et al. Early structural and metabolic cardiac remodelling in response to inducible adipose triglyceride lipase ablation. Cardiovasc Res 99 (2013), 442–451.
25. Kuang, M., Febbraio, M., Wagg, C., Lopaschuk, G.D., Dyck, J.R., Fatty acid translocase/CD36 deficiency does not energetically or functionally compromise hearts before or after ischemia. Circulation 109 (2004), 1550–1557.
26. Lehman, J.J., Boudina, S., Banke, N.H., et al. The transcriptional coactivator PGC-1alpha is essential for maximal and efficient cardiac mitochondrial fatty acid oxidation and lipid homeostasis. Am J Physiol Heart Circ Physiol 295 (2008), H185–H196.
27. Luptak, I., Balschi, J.A., Xing, Y., Leone, T.C., Kelly, D.P., Tian, R., Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization. Circulation 112 (2005), 2339–2346.
28. Kolwicz, S.C. Jr., Olson, D.P., Marney, L.C., Garcia-Menendez, L., Synovec, R.E., Tian, R., Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. Circ Res 111 (2012), 728–738.
29. Okere, I.C., Young, M.E., McElfresh, T.A., et al. Low carbohydrate/high-fat diet attenuates cardiac hypertrophy, remodeling, and altered gene expression in hypertension. Hypertension 48 (2006), 1116–1123.
30. Berthiaume, J.M., Young, M.E., Chen, X., McElfresh, T.A., Yu, X., Chandler, M.P., Normalizing the metabolic phenotype after myocardial infarction: Impact of subchronic high fat feeding. J Mol Cell Cardiol 53 (2012), 125–133.
31. Okere, I.C., Chess, D.J., McElfresh, T.A., et al. High-fat diet prevents cardiac hypertrophy and improves contractile function in the hypertensive dahl salt-sensitive rat. Clin Exp Pharmacol Physiol 32 (2005), 825–831.
32. Raher, M.J., Thibault, H.B., Buys, E.S., et al. A short duration of high-fat diet induces insulin resistance and predisposes to adverse left ventricular remodeling after pressure overload. Am J Physiol Heart Circ Physiol 295 (2008), H2495–H2502.
33. Stanley, W.C., Dabkowski, E.R., Ribeiro, R.F. Jr., O'Connell, K.A., Dietary fat and heart failure: moving from lipotoxicity to lipoprotection. Circ Res 110 (2012), 764–776.
34. Chiu, H.C., Kovacs, A., Blanton, R.M., et al. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 96 (2005), 225–233.
35. Chiu, H.C., Kovacs, A., Ford, D.A., et al. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 107 (2001), 813–822.
36. Opie, L.H., Knuuti, J., The adrenergic-fatty acid load in heart failure. J Am Coll Cardiol 54 (2009), 1637–1646.
37. He, L., Kim, T., Long, Q., et al. Carnitine palmitoyltransferase-1b deficiency aggravates pressure overload-induced cardiac hypertrophy caused by lipotoxicity. Circulation 126 (2012), 1705–1716.
38. Tucci, S., Flogel, U., Hermann, S., Sturm, M., Schafers, M., Spiekerkoetter, U., Development and pathomechanisms of cardiomyopathy in very long–chain acyl-CoA dehydrogenase deficient (VLCAD(−/−) mice. Biochim Biophys Acta 1842 (2014), 677–685.
39. Oka, S., Zhai, P., Yamamoto, T., et al. Peroxisome proliferator activated receptor-alpha association with silent information regulator 1 suppresses cardiac fatty acid metabolism in the failing heart. Circ Heart Fail 8 (2015), 1123–1132.
40. Alrob, O.A., Sankaralingam, S., Ma, C., et al. Obesity-induced lysine acetylation increases cardiac fatty acid oxidation and impairs insulin signalling. Cardiovasc Res 103 (2014), 485–497.
41. Jing, E., O'Neill, B.T., Rardin, M.J., et al. Sirt3 regulates metabolic flexibility of skeletal muscle through reversible enzymatic deacetylation. Diabetes 62 (2013), 3404–3417.
42. Reibel, D.K., Uboh, C.E., Kent, R.L., Altered coenzyme A and carnitine metabolism in pressure-overload hypertrophied hearts. Am J Physiol 244 (1983), H839–H843.
43. Regitz, V., Shug, A.L., Fleck, E., Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. Am J Cardiol 65 (1990), 755–760.
44. Lee, C.F., Tian, R., Mitochondrion as a target for heart failure therapy—role of protein lysine acetylation. Circ J 79 (2015), 1863–1870.
45. Depré C., Vanoverschelde, J.-L.J., Taegtmeyer, H., Glucose for the heart. Circulation 99 (1999), 578–588.
46. Riehle, C., Abel, E.D., Insulin signaling and heart failure. Circ Res 118 (2016), 1151–1169.
47. Harmancey, R., Lam, T.N., Lubrano, G.M., Guthrie, P.H., Vela, D., Taegtmeyer, H., Insulin resistance improves metabolic and contractile efficiency in stressed rat heart. FASEB J 26 (2012), 3118–3126.
48. Doenst, T., Pytel, G., Schrepper, A., et al. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovasc Res 86 (2010), 461–470.
49. Helfand, B.K., Maselli, N.J., Lessard, D.M., et al. Elevated serum glucose levels and survival after acute heart failure: a population-based perspective. Diab Vasc Dis Res 12 (2015), 119–125.
50. Sud, M., Wang, X., Austin, P.C., et al. Presentation blood glucose and death, hospitalization, and future diabetes risk in patients with acute heart failure syndromes. Eur Heart J 36 (2015), 924–931.
51. Dei Cas, A., Khan, S.S., Butler, J., et al. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. J Am Coll Cardiol HF 3 (2015), 136–145.
52. Sung, M.M., Hamza, S.M., Dyck, J.R.B., Myocardial metabolism in diabetic cardiomyopathy: potential therapeutic targets. Antioxid Redox Signal 22 (2015), 1606–1630.
53. Wende, A.R., Post-translational modifications of the cardiac proteome in diabetes and heart failure. Proteomic Clin Appl 10 (2016), 25–38.
54. Shao, D., Tian, R., Glucose transporters in cardiac metabolism and hypertrophy. Compr Physiol 6 (2015), 331–351.
55. Kundu, B.K., Zhong, M., Sen, S., Davogustto, G., Keller, S.R., Taegtmeyer, H., Remodeling of glucose metabolism precedes pressure overload-induced left ventricular hypertrophy: review of a hypothesis. Cardiology 130 (2015), 211–220.
56. Azam, M.A., Wagg, C.S., Massé S., et al. Feeding the fibrillating heart: dichloroacetate improves cardiac contractile dysfunction following VF. Am J Physiol Heart Circ Physiol 309 (2015), H1543–H1553.
57. Grossman, A.N., Opie, L.H., Beshansky, J.R., Ingwall, J.S., Rackley, C.E., Selker, H.P., Glucose-insulin-potassium revived. Circulation 127 (2013), 1040–1048.
58. Joost, H.G., Bell, G.I., Best, J.D., et al. Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol Endocrinol Metab 282 (2002), E974–E976.
59. Aerni-Flessner, L., Abi-Jaoude, M., Koenig, A., Payne, M., Hruz, P.W., GLUT4, GLUT1, and GLUT8 are the dominant GLUT transcripts expressed in the murine left ventricle. Cardiovasc Diabetol, 11, 2012, 63.
60. Razeghi, P., Young, M.E., Alcorn, J.L., Moravec, C.S., Frazier, O.H., Taegtmeyer, H., Metabolic gene expression in fetal and failing human heart. Circulation 104 (2001), 2923–2931.
61. Ciccarelli, M., Chuprun, J.K., Rengo, G., et al. G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. Circulation 123 (2011), 1953–1962.
62. Bishop, S.P., Altschuld, R.A., Increased glycolytic metabolism in cardiac hypertrophy and congestive failure. Am J Physiol 218 (1970), 153–159.
63. Liao, R., Jain, M., Cui, L., et al. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation 106 (2002), 2125–2131.
64. Pereira, R.O., Wende, A.R., Olsen, C., et al. Inducible overexpression of GLUT1 prevents mitochondrial dysfunction and attenuates structural remodeling in pressure overload but does not prevent left ventricular dysfunction. J Am Heart Assoc, 2, 2013, e000301.
65. Pereira, R.O., Wende, A.R., Olsen, C., et al. GLUT1 deficiency in cardiomyocytes does not accelerate the transition from compensated hypertrophy to heart failure. J Mol Cell Cardiol 72 (2014), 95–103.
66. Tian, R., Abel, E.D., Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis. Circulation 103 (2001), 2961–2966.
67. DeBosch, B.J., Chen, Z., Finck, B.N., Chi, M., Moley, K.H., Glucose transporter-8 (GLUT8) mediates glucose intolerance and dyslipidemia in high-fructose diet-fed male mice. Mol Endocrinol 27 (2013), 1887–1896.
68. Heerspink, H.J., Perkins, B.A., Fitchett, D.H., Husain, M., Cherney, D.Z., Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134 (2016), 752–772.
69. Pham, D., Albuquerque Rocha, N., McGuire, D.K., Neeland, I.J., Impact of empagliflozin in patients with diabetes and heart failure. Trends Cardiovasc Med 27 (2016), 144–151.
70. Banerjee, S.K., McGaffin, K.R., Pastor-Soler, N.M., Ahmad, F., SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res 84 (2009), 111–118.
71. Kashiwagi, Y., Nagoshi, T., Yoshino, T., et al. Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia-reperfusion injury in mice. PLoS One, 10, 2015, e0130605.
72. Son, N.-H., Ananthakrishnan, R., Yu, S., et al. Cardiomyocyte aldose reductase causes heart failure and impairs recovery from ischemia. PLoS One, 7, 2012, e46549.
73. Vimercati, C., Qanud, K., Mitacchione, G., et al. Beneficial effects of acute inhibition of the oxidative pentose phosphate pathway in the failing heart. Am J Physiol Heart Circ Physiol 306 (2014), H709–H717.
74. Burke, M.A., Chang, S., Wakimoto, H., et al. Molecular profiling of dilated cardiomyopathy that progresses to heart failure. JCI Insight, 1, 2016, e86898.
75. Ussher, J.R., Jaswal, J.S., Lopaschuk, G.D., Pyridine nucleotide regulation of cardiac intermediary metabolism. Circ Res 111 (2012), 628–641.
76. Hecker, P.A., Leopold, J.A., Gupte, S.A., Recchia, F.A., Stanley, W.C., Impact of glucose-6-phosphate dehydrogenase deficiency on the pathophysiology of cardiovascular disease. Am J Physiol Heart Circ Physiol 304 (2013), H491–H500.
77. Hardivillé S., Hart, G.W., Nutrient regulation of signaling, transcription, and cell physiology by O-GlcNAcylation. Cell Metab 20 (2014), 208–213.
78. Lunde, I.G., Aronsen, J.M., Kvaløy, H., et al. Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure. Physiol Genomics 44 (2012), 162–172.
79. Marsh, S.A., Collins, H.E., Chatham, J.C., Protein O-GlcNAcylation and cardiovascular (patho)physiology. J Biol Chem 289 (2014), 34449–34456.
80. Dassanayaka, S., Jones, S.P., O-GlcNAc and the cardiovascular system. Pharmacol Ther 142 (2014), 62–71.
81. Erickson, J.R., Pereira, L., Wang, L., et al. Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature 502 (2013), 372–376.
82. Zhu-Mauldin, X., Marsh, S.A., Zou, L., Marchase, R.B., Chatham, J.C., Modification of STIM1 by O-linked N-acetylglucosamine (O-GlcNAc) attenuates store-operated calcium entry in neonatal cardiomyocytes. J Biol Chem 287 (2012), 39094–39106.
83. 2+ sensitivity in diabetic cardiac muscle. Diabetes 64 (2015), 3573–3587.
84. Ngoh, G.A., Watson, L.J., Facundo, H.T., Jones, S.P., Augmented O-GlcNAc signaling attenuates oxidative stress and calcium overload in cardiomyocytes. Amino Acids 40 (2011), 895–911.
85. Kimura, I., Inoue, D., Maeda, T., et al. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci U S A 108 (2011), 8030–8035.
86. Valayannopoulos, V., Bajolle, F., Arnoux, J.B., et al. Successful treatment of severe cardiomyopathy in glycogen storage disease type III With D, L-3-hydroxybutyrate, ketogenic and high-protein diet. Pediatr Res 70 (2011), 638–641.
87. Al-Zaid, N.S., Dashti, H.M., Mathew, T.C., Juggi, J.S., Low carbohydrate ketogenic diet enhances cardiac tolerance to global ischaemia. Acta Cardiol 62 (2007), 381–389.
88. Liu, J., Wang, P., Zou, L., et al. High-fat, low-carbohydrate diet promotes arrhythmic death and increases myocardial ischemia-reperfusion injury in rats. Am J Physiol Heart Circ Physiol 307 (2014), H598–H608.
89. Wang, P., Tate, J.M., Lloyd, S.G., Low carbohydrate diet decreases myocardial insulin signaling and increases susceptibility to myocardial ischemia. Life Sci 83 (2008), 836–844.
90. Schugar, R.C., Moll, A.R., Andre d'Avignon, D., Weinheimer, C.J., Kovacs, A., Crawford, P.A., Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling. Mol Metab 3 (2014), 754–769.
91. Stowe, K.A., Burgess, S.C., Merritt, M., Sherry, A.D., Malloy, C.R., Storage and oxidation of long-chain fatty acids in the C57/BL6 mouse heart as measured by NMR spectroscopy. FEBS Lett 580 (2006), 4282–4287.
92. Cotter, D.G., Schugar, R.C., Crawford, P.A., Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol 304 (2013), H1060–H1076.
93. Janardhan, A., Chen, J., Crawford, P.A., Altered systemic ketone body metabolism in advanced heart failure. Tex Heart Inst J 38 (2011), 533–538.
94. Lommi, J., Koskinen, P., Naveri, H., Harkonen, M., Kupari, M., Heart failure ketosis. J Intern Med 242 (1997), 231–238.
95. Packer, M., Pathophysiology of chronic heart failure. Lancet 340 (1992), 88–92.
96. Kupari, M., Lommi, J., Ventila, M., Karjalainen, U., Breath acetone in congestive heart failure. Am J Cardiol 76 (1995), 1076–1078.
97. Marcondes-Braga, F.G., Gutz, I.G., Batista, G.L., et al. Exhaled acetone as a new biomaker of heart failure severity. Chest 142 (2012), 457–466.
98. Yokokawa, T., Sugano, Y., Shimouchi, A., et al. Exhaled acetone concentration is related to hemodynamic severity in patients with non-ischemic chronic heart failure. Circ J 80 (2016), 1178–1186.
99. Zordoky, B.N., Sung, M.M., Ezekowitz, J., et al. Metabolomic fingerprint of heart failure with preserved ejection fraction. PLoS One, 10, 2015, e0124844.
100. Aubert, G., Martin, O.J., Horton, J.L., et al. The failing heart relies on ketone bodies as a fuel. Circulation 133 (2016), 698–705.
101. Bedi, K.C. Jr., Snyder, N.W., Brandimarto, J., et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation 133 (2016), 706–716.
102. Shimazu, T., Hirschey, M.D., Newman, J., et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339 (2013), 211–214.
103. Hakuno, D., Hamba, Y., Toya, T., Adachi, T., Plasma amino acid profiling identifies specific amino acid associations with cardiovascular function in patients with systolic heart failure. PLoS One, 10, 2015, e0117325.
104. Pasini, E., Aquilani, R., Dioguardi, F.S., D'Antona, G., Gheorghiade, M., Taegtmeyer, H., Hypercatabolic syndrome: molecular basis and effects of nutritional supplements with amino acids. Am J Cardiol 101 (2008), 11E–15E.
105. Lai, L., Leone, T.C., Keller, M.P., et al. Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach. Circ Heart Fail 7 (2014), 1022–1031.
106. Sun, H., Olson, K.C., Gao, C., et al. Catabolic defect of branched-chain amino acids promotes heart failure. Circulation 133 (2016), 2038–2049.
107. Ito, T., Kimura, Y., Uozumi, Y., et al. Taurine depletion caused by knocking out the taurine transporter gene leads to cardiomyopathy with cardiac atrophy. J Mol Cell Cardiol 44 (2008), 927–937.
108. Schaffer, S.W., Shimada-Takaura, K., Jong, C.J., Ito, T., Takahashi, K., Impaired energy metabolism of the taurine deficient heart. Amino Acids 48 (2016), 549–558.
109. Jong, C.J., Azuma, J., Schaffer, S., Mechanism underlying the antioxidant activity of taurine: prevention of mitochondrial oxidant production. Amino Acids 42 (2012), 2223–2232.
110. Ramila, K.C., Jong, C.J., Pastukh, V., Ito, T., Azuma, J., Schaffer, S.W., Role of protein phosphorylation in excitation-contraction coupling in taurine deficient hearts. Am J Physiol Heart Circ Physiol 308 (2015), H232–H239.
111. Azuma, J., Sawamura, A., Awata, N., Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J 56 (1992), 95–99.
112. Beyranvand, M.R., Khalafi, M.K., Roshan, V.D., Choobineh, S., Parsa, S.A., Piranfar, M.A., Effect of taurine supplementation on exercise capacity of patients with heart failure. J Cardiol 57 (2011), 333–337.
113. Carubelli, V., Castrini, A.I., Lazzarini, V., Gheorghiade, M., Metra, M., Lombardi, C., Amino acids and derivatives, a new treatment of chronic heart failure?. Heart Fail Rev 20 (2015), 39–51.
114. Aquilani, R., Viglio, S., Iadarola, P., et al. Oral amino acid supplements improve exercise capacities in elderly patients with chronic heart failure. Am J Cardiol 101 (2008), 104E–110E.
115. Lombardi, C., Carubelli, V., Lazzarini, V., et al. Effects of oral amino acid supplements on functional capacity in patients with chronic heart failure. Clin Med Insights 8 (2014), 39–44.
116. Tanada, Y., Shioi, T., Kato, T., Kawamoto, A., Okuda, J., Kimura, T., Branched-chain amino acids ameliorate heart failure with cardiac cachexia in rats. Life Sci 137 (2015), 20–27.
117. Anker, S.D., Ponikowski, P., Varney, S., et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349 (1997), 1050–1053.
118. Shiojima, I., Sato, K., Izumiya, Y., et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115 (2005), 2108–2118.
119. Riehle, C., Wende, A.R., Sena, S., et al. Insulin receptor substrate signaling suppresses neonatal autophagy in the heart. J Clin Invest 123 (2013), 5319–5333.
120. McMullen, J.R., Sherwood, M.C., Tarnavski, O., et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 109 (2004), 3050–3055.
121. Shende, P., Plaisance, I., Morandi, C., et al. Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice. Circulation 123 (2011), 1073–1082.
122. Lu, Z., Xu, X., Fassett, J., et al. Loss of the eukaryotic initiation factor 2alpha kinase general control nonderepressible 2 protects mice from pressure overload-induced congestive heart failure without affecting ventricular hypertrophy. Hypertension 63 (2014), 128–135.
123. Hein, S., Arnon, E., Kostin, S., et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107 (2003), 984–991.
124. Knaapen, M.W., Davies, M.J., De Bie, M., Haven, A.J., Martinet, W., Kockx, M.M., Apoptotic versus autophagic cell death in heart failure. Cardiovasc Res 51 (2001), 304–312.
125. Kassiotis, C., Ballal, K., Wellnitz, K., et al. Markers of autophagy are downregulated in failing human heart after mechanical unloading. Circulation 120 (2009), S191–S197.
126. Zhu, H., Tannous, P., Johnstone, J.L., et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. J Clin Invest 117 (2007), 1782–1793.
127. Shirakabe, A., Zhai, P., Ikeda, Y., et al. Drp1-dependent mitochondrial autophagy plays a protective role against pressure overload-induced mitochondrial dysfunction and heart failure. Circulation 133 (2016), 1249–1263.
128. Nakai, A., Yamaguchi, O., Takeda, T., et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med 13 (2007), 619–624.
129. Li, D.L., Wang, Z.V., Ding, G., et al. Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification. Circulation 133 (2016), 1668–1687.
130. Predmore, J.M., Wang, P., Davis, F., et al. Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies. Circulation 121 (2010), 997–1004.
131. Birks, E.J., Latif, N., Enesa, K., et al. Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy. Cardiovasc Res 79 (2008), 472–480.
132. Day, S.M., Divald, A., Wang, P., et al. Impaired assembly and post-translational regulation of 26S proteasome in human end-stage heart failure. Circ Heart Fail 6 (2013), 544–549.
133. Ghosh, N., Haddad, H., Atrial natriuretic peptides in heart failure: pathophysiological significance, diagnostic and prognostic value. Can J Physiol Pharmacol 89 (2011), 587–591.
134. Lafontan, M., Moro, C., Berlan, M., Crampes, F., Sengenes, C., Galitzky, J., Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab 19 (2008), 130–137.
135. Tenenbaum, A., Fisman, E.Z., Impaired glucose metabolism in patients with heart failure: pathophysiology and possible treatment strategies. Am J Cardiovasc Drugs 4 (2004), 269–280.
136. Rame, J.E., Metabolic staging in human heart failure: circulating acylcarnitines and the failing heart's energetic signature. J Am Coll Cardiol 67 (2016), 300–302.
137. Atar, D., Spiess, M., Mandinova, A., Cierpka, H., Noll, G., Luscher, T.F., Carnitine—from cellular mechanisms to potential clinical applications in heart disease. Eur J Clin Invest 27 (1997), 973–976.
138. Folmes, C.D., Clanachan, A.S., Lopaschuk, G.D., Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis. Curr Atheroscler Rep 7 (2005), 63–70.
139. Lopatin, Y.M., Rosano, G.M., Fragasso, G., et al. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. Int J Cardiol 203 (2016), 909–915.
140. Zhang, L., Lu, Y., Jiang, H., et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol 59 (2012), 913–922.
141. Fragasso, G., Salerno, A., Lattuada, G., et al. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure. Heart 97 (2011), 1495–1500.
142. Holubarsch, C.J., Rohrbach, M., Karrasch, M., et al. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci 113 (2007), 205–212.
143. Ferrari, R., Merli, E., Cicchitelli, G., Mele, D., Fucili, A., Ceconi, C., Therapeutic effects of L–carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci 1033 (2004), 79–91.